These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 2020763)

  • 1. Nimorazole as a hypoxic radiosensitizer in the treatment of supraglottic larynx and pharynx carcinoma. First report from the Danish Head and Neck Cancer Study (DAHANCA) protocol 5-85.
    Overgaard J; Sand Hansen H; Lindeløv B; Overgaard M; Jørgensen K; Rasmusson B; Berthelsen A
    Radiother Oncol; 1991; 20 Suppl 1():143-9. PubMed ID: 2020763
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85.
    Overgaard J; Hansen HS; Overgaard M; Bastholt L; Berthelsen A; Specht L; Lindeløv B; Jørgensen K
    Radiother Oncol; 1998 Feb; 46(2):135-46. PubMed ID: 9510041
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IAEA-HypoX. A randomized multicenter study of the hypoxic radiosensitizer nimorazole concomitant with accelerated radiotherapy in head and neck squamous cell carcinoma.
    Hassan Metwally MA; Ali R; Kuddu M; Shouman T; Strojan P; Iqbal K; Prasad R; Grau C; Overgaard J
    Radiother Oncol; 2015 Jul; 116(1):15-20. PubMed ID: 25913070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene expression classifier predicts for hypoxic modification of radiotherapy with nimorazole in squamous cell carcinomas of the head and neck.
    Toustrup K; Sørensen BS; Lassen P; Wiuf C; Alsner J; Overgaard J;
    Radiother Oncol; 2012 Jan; 102(1):122-9. PubMed ID: 21996521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interactions of radiation, cyclophosphamide and nimorazole in a C3H mammary carcinoma in vivo.
    Zachariae C; Overgaard J
    Int J Radiat Oncol Biol Phys; 1986 Aug; 12(8):1445-8. PubMed ID: 3759571
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Compliance and toxicity of the hypoxic radiosensitizer nimorazole in the treatment of patients with head and neck squamous cell carcinoma (HNSCC).
    Metwally MA; Frederiksen KD; Overgaard J
    Acta Oncol; 2014 May; 53(5):654-61. PubMed ID: 24328536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comment on: A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the the Danish Head and Neck Cancer Study (DAHNCA) Protocol 5-85.
    Ben-Josef E
    Radiother Oncol; 1998 Sep; 48(3):344-6. PubMed ID: 9925257
    [No Abstract]   [Full Text] [Related]  

  • 8. Pilot study of nimorazole as a hypoxic-cell sensitizer with the "chart" regimen in head and neck cancer.
    Cottrill CP; Bishop K; Walton MI; Henk JM
    Int J Radiat Oncol Biol Phys; 1998 Nov; 42(4):807-10. PubMed ID: 9845101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DAHANCA 10 - Effect of darbepoetin alfa and radiotherapy in the treatment of squamous cell carcinoma of the head and neck. A multicenter, open-label, randomized, phase 3 trial by the Danish head and neck cancer group.
    Overgaard J; Hoff CM; Hansen HS; Specht L; Overgaard M; Lassen P; Andersen E; Johansen J; Andersen LJ; Evensen JF; Alsner J; Grau C
    Radiother Oncol; 2018 Apr; 127(1):12-19. PubMed ID: 29523409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Misonidazole combined with split-course radiotherapy in the treatment of invasive carcinoma of larynx and pharynx: report from the DAHANCA 2 study.
    Overgaard J; Hansen HS; Andersen AP; Hjelm-Hansen M; Jørgensen K; Sandberg E; Berthelsen A; Hammer R; Pedersen M
    Int J Radiat Oncol Biol Phys; 1989 Apr; 16(4):1065-8. PubMed ID: 2649462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radiotherapy quality assurance of the IAEA-HypoX trial of the accelerated radiotherapy in the treatment of head and neck squamous cell carcinoma with or without the hypoxic radiosensitizer nimorazole.
    Hassan Metwally MA; Ali R; Kuddu M; Shouman T; Strojan P; Overgaard J; Grau C
    Acta Oncol; 2015; 54(9):1673-7. PubMed ID: 26397148
    [No Abstract]   [Full Text] [Related]  

  • 12. Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial.
    Overgaard J; Hansen HS; Specht L; Overgaard M; Grau C; Andersen E; Bentzen J; Bastholt L; Hansen O; Johansen J; Andersen L; Evensen JF
    Lancet; 2003 Sep; 362(9388):933-40. PubMed ID: 14511925
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Study of the population pharmacokinetic characteristics of nimorazole in head and neck cancer patients treated in the DAHANCA-5 trial.
    Hassan Metwally MA; Jansen JA; Overgaard J
    Clin Oncol (R Coll Radiol); 2015 Mar; 27(3):168-75. PubMed ID: 25530485
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Locally advanced head and neck cancer treated with accelerated radiotherapy, the hypoxic modifier nimorazole and weekly cisplatin. Results from the DAHANCA 18 phase II study.
    Bentzen J; Toustrup K; Eriksen JG; Primdahl H; Andersen LJ; Overgaard J
    Acta Oncol; 2015 Jul; 54(7):1001-7. PubMed ID: 25629651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: results from the DAHANCA 5 randomised double-blind placebo-controlled trial.
    Overgaard J; Eriksen JG; Nordsmark M; Alsner J; Horsman MR;
    Lancet Oncol; 2005 Oct; 6(10):757-64. PubMed ID: 16198981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of prognostic and predictive value of CA IX in radiotherapy of squamous cell carcinoma of the head and neck with known modifiable hypoxia: an evaluation of the DAHANCA 5 study.
    Eriksen JG; Overgaard J;
    Radiother Oncol; 2007 Jun; 83(3):383-8. PubMed ID: 17543403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does transfusion improve the outcome for HNSCC patients treated with radiotherapy? - results from the randomized DAHANCA 5 and 7 trials.
    Hoff CM; Lassen P; Eriksen JG; Hansen HS; Specht L; Overgaard M; Grau C; Johansen J; Bentzen J; Andersen L; Evensen JF; Overgaard J
    Acta Oncol; 2011 Oct; 50(7):1006-14. PubMed ID: 21790306
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The importance of haemoglobin level and effect of transfusion in HNSCC patients treated with radiotherapy--results from the randomized DAHANCA 5 study.
    Hoff CM; Hansen HS; Overgaard M; Grau C; Johansen J; Bentzen J; Overgaard J
    Radiother Oncol; 2011 Jan; 98(1):28-33. PubMed ID: 20970213
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HPV-associated p16-expression and response to hypoxic modification of radiotherapy in head and neck cancer.
    Lassen P; Eriksen JG; Hamilton-Dutoit S; Tramm T; Alsner J; Overgaard J;
    Radiother Oncol; 2010 Jan; 94(1):30-5. PubMed ID: 19910068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic biomarkers for the response to the radiosensitizer nimorazole combined with RCTx: a pre-clinical trial in HNSCC xenografts.
    Koi L; Bitto V; Weise C; Möbius L; Linge A; Löck S; Yaromina A; Besso MJ; Valentini C; Pfeifer M; Overgaard J; Zips D; Kurth I; Krause M; Baumann M
    J Transl Med; 2023 Aug; 21(1):576. PubMed ID: 37633930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.